Biodesix

Historical price data

Biodesix is a publicly-traded diagnostic company with a mission to transform patient care through timely, personalized diagnostics, primarily in lung cancer. The company has successfully commercialized a suite of blood-based tests, including the FDA-cleared Nodify Lung® and GeneStrat® tests, which are supported by its proprietary AI-driven multi-omics platform and real-world Biodesix Lung Database®. Its strategy is twofold: expanding the clinical adoption of its diagnostic tests while capitalizing on its platform and operational expertise through a growing diagnostic development services business for life sciences partners.

A proprietary, cloud-based platform integrating multi-omics data (proteomics and genomics), machine learning, and the real-world Biodesix Lung Database® to discover, develop, and validate diagnostic tests.

Biodesix competes with large liquid biopsy leaders (Guardant Health, Foundation Medicine/Roche) in therapy selection and with specialized diagnostic firms (Veracyte) in lung nodule assessment. Its differentiation lies in its integrated multi-omics approach, lung-focused real-world database, and dual diagnostic/services business model.